Surveyed U.S. Neurologists Indicate They Would Prescribe CoLucid’s Lasmiditan to 10 Percent of Their Patients with Migraine

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicate that they would prescribe CoLucid’s lasmiditan to 10 percent of their migraine patients. Decision Resources forecasts that, in the market for acute migraine drugs, lasmiditan will earn a similar patient share of 8 percent in the U.S. by 2020 (comparable to the 2010 U.S. patient share for Merck’s Max

Feed Date: 
February 22, 2012